Shares of XOMA Corp (NASDAQ:XOMA) have received a consensus rating of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $26.13.
Several analysts have recently issued reports on the company. TheStreet cut XOMA from a “c-” rating to a “d-” rating in a research note on Monday, November 26th. ValuEngine upgraded XOMA from a “sell” rating to a “hold” rating in a research note on Tuesday, December 11th. HC Wainwright set a $36.00 price objective on XOMA and gave the company a “buy” rating in a research note on Wednesday, November 7th. Finally, Cowen reiterated a “hold” rating on shares of XOMA in a research note on Thursday, November 8th.
In other XOMA news, major shareholder Bvf Partners L. P/Il bought 2,810 shares of the company’s stock in a transaction that occurred on Wednesday, December 12th. The shares were purchased at an average price of $14.75 per share, with a total value of $41,447.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bvf Partners L. P/Il bought 21,141 shares of the company’s stock in a transaction that occurred on Thursday, November 15th. The stock was acquired at an average cost of $13.31 per share, for a total transaction of $281,386.71. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 380,177 shares of company stock worth $5,476,116. Insiders own 7.90% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in XOMA by 12.4% in the fourth quarter. BlackRock Inc. now owns 508,672 shares of the biotechnology company’s stock valued at $6,434,000 after buying an additional 56,130 shares during the last quarter. Fosun International Ltd purchased a new position in shares of XOMA during the fourth quarter worth about $3,842,000. Vanguard Group Inc grew its holdings in shares of XOMA by 1.0% during the third quarter. Vanguard Group Inc now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after purchasing an additional 3,167 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of XOMA by 1.0% during the third quarter. Vanguard Group Inc. now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after purchasing an additional 3,167 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of XOMA by 6.0% during the third quarter. Acadian Asset Management LLC now owns 101,820 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 5,769 shares during the last quarter. 42.44% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:XOMA traded up $0.13 during trading hours on Friday, reaching $12.20. 59,382 shares of the stock were exchanged, compared to its average volume of 48,365. The company has a quick ratio of 5.38, a current ratio of 5.38 and a debt-to-equity ratio of 19.16. XOMA has a twelve month low of $11.02 and a twelve month high of $29.29. The stock has a market capitalization of $102.36 million, a price-to-earnings ratio of 12.45 and a beta of 2.43.
XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.40). The company had revenue of $0.90 million during the quarter, compared to analyst estimates of $0.83 million. XOMA had a negative net margin of 129.85% and a negative return on equity of 267.64%. On average, sell-side analysts expect that XOMA will post -1.73 EPS for the current fiscal year.
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
Further Reading: How Investors Can Profit from Options Trading
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.